Bank of New York Mellon Corp Has $426,000 Stock Position in OptimizeRx Co. (NASDAQ:OPRX)

Bank of New York Mellon Corp cut its holdings in OptimizeRx Co. (NASDAQ:OPRX) by 8.8% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 87,712 shares of the company’s stock after selling 8,436 shares during the quarter. Bank of New York Mellon Corp owned 0.48% of OptimizeRx worth $426,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of OPRX. BNP Paribas Financial Markets grew its holdings in shares of OptimizeRx by 189.2% during the third quarter. BNP Paribas Financial Markets now owns 3,690 shares of the company’s stock valued at $28,000 after buying an additional 2,414 shares during the last quarter. Quest Partners LLC lifted its position in OptimizeRx by 15,965.6% in the 3rd quarter. Quest Partners LLC now owns 9,800 shares of the company’s stock valued at $76,000 after acquiring an additional 9,739 shares in the last quarter. SG Americas Securities LLC acquired a new position in OptimizeRx during the 4th quarter valued at about $51,000. Barclays PLC increased its holdings in OptimizeRx by 358.5% during the 3rd quarter. Barclays PLC now owns 26,934 shares of the company’s stock worth $208,000 after purchasing an additional 21,060 shares in the last quarter. Finally, Greenwood Capital Associates LLC raised its stake in shares of OptimizeRx by 31.5% in the fourth quarter. Greenwood Capital Associates LLC now owns 88,596 shares of the company’s stock worth $431,000 after purchasing an additional 21,240 shares during the last quarter. 76.47% of the stock is currently owned by institutional investors.

OptimizeRx Trading Down 1.1 %

OPRX opened at $8.64 on Friday. The stock has a market cap of $159.16 million, a PE ratio of -6.50 and a beta of 1.31. The business has a 50 day moving average of $6.25 and a 200-day moving average of $5.99. OptimizeRx Co. has a 52 week low of $3.78 and a 52 week high of $14.13. The company has a quick ratio of 3.23, a current ratio of 3.23 and a debt-to-equity ratio of 0.29.

Insider Buying and Selling

In other news, Director James Paul Lang purchased 321,408 shares of the business’s stock in a transaction dated Friday, March 14th. The shares were purchased at an average price of $7.60 per share, for a total transaction of $2,442,700.80. Following the completion of the acquisition, the director now directly owns 389,452 shares in the company, valued at $2,959,835.20. This represents a 472.35 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 6.10% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. Royal Bank of Canada restated a “sector perform” rating and issued a $6.00 target price (down previously from $7.00) on shares of OptimizeRx in a research note on Wednesday, January 8th. B. Riley upgraded OptimizeRx to a “strong-buy” rating in a research note on Wednesday, March 12th. Stephens began coverage on OptimizeRx in a research note on Friday, December 20th. They set an “equal weight” rating and a $5.50 target price on the stock. Lake Street Capital restated a “buy” rating and set a $11.00 price target on shares of OptimizeRx in a research report on Tuesday, December 24th. Finally, JMP Securities restated a “market outperform” rating and set a $8.00 price objective on shares of OptimizeRx in a report on Thursday, February 6th. Three equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, OptimizeRx currently has a consensus rating of “Moderate Buy” and an average price target of $9.06.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.